In a mouse model, IMO-2055, a TLR 9 agonist, exerted anti-tumor effects by increasing IL-6 and 12 levels with only little inflammatory reaction (Wang et al. 2004; Ojik et al. 2003; Damiano et al. 2006). This evidence concerns the gene IL6 and neoplasm.